Induced Proximity Platform, Amgen Research, Thousand Oaks, CA, United States.
Induced Proximity Platform, Amgen Research, Thousand Oaks, CA, United States.
Methods Enzymol. 2023;681:23-39. doi: 10.1016/bs.mie.2022.08.027. Epub 2022 Sep 23.
The discovery of new small molecule ligands for E3 ligases will enable the creation of novel proteolysis targeting chimeras (PROTACs) and molecular glues to tackle traditionally undruggable proteins. Diversifying both the chemical matter for each E3 ligase and the type of ligases will be important to fully capture the potential of these targeted protein degradation modalities. A key step in this process is to establish an integrated screening platform for the rapid identification and optimization of small molecule ligands for E3 ligases. Here, we provide a method to evaluate E3 ligase ligands using AlphaScreen technology. AlphaScreen allows for the evaluation of a wide array of molecular interactions and is utilized extensively in small molecule screening campaigns. This bead-based proximity technology offers facile development for interactions across a wide range of affinities and can be adapted to interrogate E3 ligase-degron interactions. In this protocol, we demonstrate the development of AlphaScreen for E3 ligase ligand competition assays toward the discovery of new ligands for E3 ligases.
发现新的小分子配体 E3 连接酶将能够创建新型的蛋白水解靶向嵌合体(PROTAC)和分子胶,以解决传统上难以成药的蛋白质。对于每种 E3 连接酶的化学物质和连接酶的类型进行多样化,对于充分发挥这些靶向蛋白降解方式的潜力非常重要。该过程中的一个关键步骤是建立一个集成的筛选平台,用于快速鉴定和优化 E3 连接酶的小分子配体。在这里,我们提供了一种使用 AlphaScreen 技术评估 E3 连接酶配体的方法。AlphaScreen 允许评估广泛的分子相互作用,并在小分子筛选活动中得到广泛应用。这种基于珠的接近技术易于开发各种亲和力的相互作用,并且可以适应于探测 E3 连接酶-降解基序相互作用。在本方案中,我们展示了针对 E3 连接酶配体竞争测定法的 AlphaScreen 的开发,用于发现新的 E3 连接酶配体。